Investor Presentaiton
Life Science Ingredients
(1) As on Sep 30, 2019
Pharmaceuticals
4
Strong Pipeline of Products With Deep R&D Capabilities
▸ Strong R&D capabilities demonstrated by complex and niche product filings including 505(b)(2) in radiopharma
▸ Strong R&D support with a dedicated workforce of more than 500 R&D professionals. Over 852 patents filed till FY19
Strong pipeline of 8 products in the Radiopharmaceuticals business including I-131 mIBG with market size of over USD 300 million
44 commercial APIs, 96 US DMFS filed¹
Pharmaceuticals R&D Spending (Rs Cr.)
Product pipeline as on Sep 30, 2019
Dosage (Orals)
Steriles
261
260
244
Region
Total
217
Approval
Pending
Filings
Total
Filings
Approval
Pending
US
96
61
35
15
13
2
Canada
23
23
0
17
16
1
Europe
36
33
3
4
4
0
FY 16
FY17
FY18
FY19
ROW
41
36
5
9
9
0
Broad product portfolio of ~90 products driven by R&D capabilities and Chemistry
expertise
▸ Strong R&D led product pipeline of over 30 products, planned to be launched over
the next 3-5 years
▸ Expertise in a large number of chemical processes; highly equipped laboratories
with advanced equipments and analytical facilities
Over 70 scientists in the LSI business
4 R&D centers - Gajraula, Noida, Ambernath & Bharuch
147 patents filed till FY19
Life Science Ingredients (LSI) – Product Pipeline / New Launches
#
Till March
31, 2018
55
Total
New Launches
FY19
6
61
Specialty
Intermediates
Nutritional
22
1
23
Products
Life Science
Chemicals
7
0
7
Total
84
7
91
JUBILANT
LIFESCIENCESView entire presentation